Lv5
1420 积分 2023-09-24 加入
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
10天前
已完结
Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis effect in graft outcomes
1个月前
已完结
Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding
5个月前
已完结
Ethiodized Oil–based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion
6个月前
已完结
Ethiodized Oil–based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion
6个月前
已完结
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma
8个月前
已完结
RECIST 1.1—Update and clarification: From the RECIST committee
8个月前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
8个月前
已完结
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
8个月前
已完结
Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study
8个月前
已完结
皖公网安备34019202002308
